The possibility of determining residual urine and the effectiveness of alpha-1-blocker therapy in patients with prostate cancer using the innovative domestic uroflowmetric complex “Sigma„

Goals and objectives . To evaluate the possibility of residual urine verification in the process of uroflowmetric monitoring (UFM) using an innovative domestic uroflowmetric complex «Sigma». Patients and methods . Under our observation was a group of patients observed with the diagnosis of «benign prostatic hyperplasia (BPH)» in the centre «Urinary Pathology», Vladivostok. The mean age in the group (36 cases) was 60,5+ 8,2 years, ranging from 50 to 73 years. The duration of therapy ranged from 2 to 24 months, with an average of 8,4 + 5,5 months. Results . Using the method of mathematical statistics X2 it was shown that the domestic uroflowmetric complex «Sigma» allows to reliably determine residual urine in the process of uroflowmetric monitoring, in addition to this the connection between the symptom of incomplete emptying of the bladder, according to the IPSS questionnaire, and residual urine recorded with the help of uroflowmetric complex was refuted. As a result of alpha-1-adrenoblocker treatment, there was a significant reduction in the severity of clinical symptoms and levelling of lower urinary tract dysfunction. Conclusion . In this study it was proved that the determination of residual urine with the help of domestic uroflowmetric complex «Sigma» is possible. This was verified with a high degree of reliability by ultrasound examination of residual urine volume. It was confirmed that the use of alpha-1-adrenoblockers can statistically significantly reduce the incidence of residual urine formation. In addition, alpha1-adrenoblocker administration has been shown to reduce both irritative and obstructive symptoms of urinary disorders.